Diurnal Group plc operates as a specialty pharma company. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Its product pipeline includes Infacort for use in children suffering from adrenal insufficiency; and Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia in adult patients, as well as adrenal insufficiency.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-29-20682069
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£1.04 million
Profitability
Miscellaneous
Employees23
Next Earnings DateN/A
OptionableNot Optionable
Diurnal Group (LON:DNL) Frequently Asked Questions
What is Diurnal Group's stock symbol?
Diurnal Group trades on the London Stock Exchange (LON) under the ticker symbol "DNL."
How were Diurnal Group's earnings last quarter?
Diurnal Group PLC (LON:DNL) posted its quarterly earnings results on Monday, March, 12th. The company reported ($12.70) earnings per share for the quarter. View Diurnal Group's Earnings History.
Has Diurnal Group been receiving favorable news coverage?
Media headlines about DNL stock have trended somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Diurnal Group earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Diurnal Group.
Who are some of Diurnal Group's key competitors?
Some companies that are related to Diurnal Group include ESSA Pharma (EPI), Harvest One Cannabis (HVT), Delta 9 Cannabis (NINE), Biosyent (RX), Invion (IVX), Depomed (ASRT), Science in Sport (SIS), Pediapharm (MDP), Eve & Co Inc (EVE), Zomedica Pharmaceuticals (ZOM), MMJ Group (MMJ), InMed Pharmaceuticals (IN), MGC Pharmaceuticals (MXC), Viridium Pacific Group (VIR) and Cipher Pharmaceuticals (CPH).
What other stocks do shareholders of Diurnal Group own?
Who are Diurnal Group's key executives?
Diurnal Group's management team includes the folowing people:
- Dr. Martin Whitaker B.Sc., BSc, Ph.D., CEO & Exec. Director
- Mr. Richard Edward Bungay BSc, ACA, CFO,Director & Company Sec. (Age 50)
- Prof. Richard Ross, Chief Scientific Officer & Exec. Director
- Mr. Michael Withe, Commercial Director
- Mr. John Porter, Medical Director
How do I buy shares of Diurnal Group?
Shares of DNL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Diurnal Group's stock price today?
One share of DNL stock can currently be purchased for approximately GBX 33.
How big of a company is Diurnal Group?
What is Diurnal Group's official website?
How can I contact Diurnal Group?
Diurnal Group's mailing address is Heath Park, CARDIFF, CF14 4UJ, United Kingdom. The company can be reached via phone at +44-29-20682069.
MarketBeat Community Rating for Diurnal Group (LON DNL)
MarketBeat's community ratings are surveys of what our community members think about Diurnal Group and other stocks. Vote "Outperform" if you believe DNL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNL will underperform the S&P 500 over the long term. You may vote once every thirty days.
